AbbVie, Elahere

AbbVie’s Elahere wins European approval for certain ovarian cancers
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: Skorzewiak via Shutterstock. The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab ...
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab soravtansine) for treating platinum-resistant ovarian cancer. The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive,
AbbVie receives EC approval of Elahere
AbbVie (ABBV) announced the European Commission, or EC, granted marketing authorization for Elahere for the treatment of adult patients with
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that closed in February.
AbbVie's Elahere Approved in Europe for FRα-Positive Ovarian Cancer
NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate receptor-alpha (FRα)-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
European Commission Approves AbbVie's ELAHERE For Platinum-Resistant Ovarian Cancer Treatment
AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive,
pharmaphorum10h
AbbVie bags EU nod for key drug from ImmunoGen takeover
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)
Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...
Zacks.com on MSN3d
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?
AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
Buy, Sell, Or Hold AbbVie Stock?
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
Entropy Technologies LP Takes $250,000 Position in AbbVie Inc. (NYSE:ABBV)
Entropy Technologies LP acquired a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) in the third quarter, ...